Profound Medical (NASDAQ: PROF; TSX: PRN) has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and...
Theravance Biopharma (NASDAQ: TBPH) has announced the launch of Power in the Periphery—a new disease education campaign to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic...
Adicet Bio (NASDAQ: ACET) has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory rheumatoid arthritis (RA). The company’s Phase 1 study is designed...
Candel Therapeutics (NASDAQ: CADL) has announced the appointment of internationally recognized expert in systems immunology and vaccinology, Bali Pulendran, PhD, to Candel’s research advisory board. Dr. Pulendran is the...
LB Pharmaceuticals (NASDAQ: LBRX) has announced the appointment of James Rawls, PharmD, as senior vice president (SVP) of regulatory affairs. With more than 25 years of regulatory leadership experience across global...
CervoMed (NASDAQ: CRVO) has announced additional data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod’s potential as a treatment for dementia with Lewy bodies (DLB). According to CervoMed, FDA feedback on...
Aquestive Therapeutics (NASDAQ: AQST) has announced that the USPTO has issued two additional patents extending protection into 2037 for Anaphylm, a novel epinephrine prodrug sublingual film. According to Aquestive, if...
Closely held PharmaJet has announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. The single-use and reusable needle-free...
Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) is an early stage commercial growth company that is pioneering a breakthrough, ultra-high-res, AI-driven intraoperative margin visualization technology called B...
Alto Neuroscience (NYSE: ANRO) announced that the FDA has granted its novel small molecule PDE4 inhibitor, ALTO-101, fast track designation for the treatment of cognitive impairment associated with schizophrenia (CIAS)...